PLoS PathogensMicrobiologyPeer-reviewed journal article
Characterization of Atypical Ebola Virus Disease in Ferrets
Wenguang CaoiD, Shihua HeiD, Helene SchulziD, Jordan WightiD, Michael Chan, Karla EmeterioiD, Guodong LiuiD, Jonathan AudetiD, Kevin Tierney, Kimberly Azaransky, Kathy Frost, Lilianne Gee, Peter McQueen, Patrick Chong, Sarah B. SulkoskyiD, Stephanie Booth, Garrett WestmacottiD, Erica Ollmann SaphireiD, Xiankun ZengiD, Logan BanadygaiD
Abstract
Ebola virus (EBOV) typically results in a severe--and often lethal--acute disease. However, increasing evidence suggests that EBOV can persist in certain immune-privileged tissues, which may then serve as reservoirs for the later reemergence of EBOV and disease recrudescence. Here, we report atypical EVD recrudescence in a ferret model inoculated with an otherwise lethal dose of EBOV and treated with low doses of a highly potent monoclonal antibody cocktail. Among 32 antibody-treated ferrets, 14 animals survived, while 8 succumbed to acute EVD within about 5-8 days. The remaining 10 animals succumbed to atypical EVD between 12 and 18 days post-infection (DPI) despite having shown no, or very minor, signs of illness during the acute phase of disease. While viremia disappeared by 14 DPI in most animals that succumbed to atypical EVD, it rebounded modestly just prior to death. Unlike animals that died of acute EVD, those that died of atypical EVD showed only a moderate systemic inflammatory response and few signs of organ dysfunction, in line with low levels of virus in the liver and spleen. Interestingly, however, ferrets that died of atypical EVD showed high levels of virus in the brain, consistent with increased markers of inflammation in the central nervous system and significant pathological changes, including a breakdown in the blood-brain barrier and severe meningoencephalitis. Not only does this study shed important light on the atypical and underappreciated manifestations of EVD, but it also establishes the ferret as a valuable model of EBOV persistence and recrudescence. AUTHOR SUMMARYOver the last several years, it has become increasingly apparent that Ebola virus is capable of persisting in survivors and, occasionally, reemerging to cause a recrudescent disease that is often distinct from the acute illness and characterized by neurological involvement. Since nearly all existing Ebola virus animal models are uniformly lethal, it has been difficult to understand the processes that lead to persistence and atypical manifestations of disease. In this study, we describe a late-onset, atypical Ebola virus disease in ferrets that was characterized by high levels of virus in the brain and significant markers of brain inflammation. Our comprehensive analysis of the pathogenic processes that contributed to this disease not only provides critical insight into Ebola virus persistence and recrudescence, but it also establishes the ferret as the first tractable model for investigating these atypical outcomes.
- organism: rat
- research focus: host-pathogen & immune response
- research focus: differential expression
- research focus: cell type annotation
- research focus: spatial domain detection
- approach: experimental assay
- Citations
- 1
- FWCI
- 4.99
- Field percentile
- top 7%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- rVSV-EBOV vaccination protects ferrets from lethal Bundibugyo virus disease
Jordan Wight, Guodong Liu, … Logan Banadyga·bioRxiv·Aug 26, 2026
- Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates
Z. A. Bornholdt, A. S. Herbert, … J. M. Dye·bioRxiv·Aug 19, 2018
- Evidence of latency reshapes our understanding of Ebola virus reservoir dynamics
John T. McCrone, Guy Baele, … Andrew Rambaut·bioRxiv·Oct 17, 2025
- Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against Ebola virus
Jonah M. Elliff, Lindsey Grady, … Wendy J. Maury·mBioPeer-reviewed·Dec 30, 2025
- Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge
Andrea Marzi, Wakako Furuyama, … Heinz Feldmann·bioRxiv·Feb 15, 2026
- Marburg and Ebola virus infections elicit a complex, muted inflammatory state in bats
A. D. Jayaprakash, A. J. Ronk, … R. Sachidanandam·bioRxiv·Apr 13, 2020